title: Approved pharmacotherapy for myopic choroidal neovascularization: a review of randomized controlled trials in ranibizumab and aflibercept.
abstract: Myopic choroidal neovascularization (mCNV) can cause severe visual impairment in highly myopic patients. We review the randomized trials of two approved pharmacotherapy for treating mCNV, including intravitreal injections of ranibizumab and aflibercept. These two vascular endothelial growth factor (VEGF) antagonists show superior ability to improve vision and reduce macular thickness, comparing with sham injections or verteporfin photodynamic therapy (vPDT). There is no severe ocular or systemic adverse reaction reported in studies associated with ranibizumab and aflibercept for mCNV. Prompt treatment with these agents can lead to a better outcome.
authors.forename: Jia-Kang
authors.initials: JK
authors.lastname: Wang
authors.forename: Tzu-Lun
authors.initials: TL
authors.lastname: Huang
authors.forename: Pei-Yuan
authors.initials: PY
authors.lastname: Su
authors.forename: Pei-Yao
authors.initials: PY
authors.lastname: Chang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D010778:Photochemotherapy; D011166:Porphyrins / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A; D000077362:Verteporfin; D015354:Vision, Low / Q000209:etiology
chemical_list: D020533:Angiogenesis Inhibitors; D011166:Porphyrins; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; D000077362:Verteporfin; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab